Caisse de dépôt et placement du Québec acquired a significant minority stake in Mexico-based medical diagnostic services group, Grupo Diagnóstico Aries. The transaction is subject to customary regulatory approvals.

(Press Release) Caisse de dépôt et placement du Québec (CDPQ), a global investment group, today announced that it will acquire a significant minority stake in Grupo Diagnóstico Aries (the “Company”), one of the fastest growing medical diagnostic services groups in Mexico. The transaction is subject to customary regulatory approvals.

Founded in 2012 and headquartered in Mexico City, Grupo Diagnóstico Aries is a consortium of nine brands with 249 locations across nine states, including three blood banks and sixteen mobile units. Additionally, the Company operates three in-house laboratories in private hospitals, and serves more than 150 clinics and public hospitals. After several strategic acquisitions and sustained organic growth, the Company has become one of Mexico’s most extensive networks of testing laboratories in the medical diagnostic services sector.

“We are very proud that a company with the record and prestige of CDPQ, with over 50 years of experience investing in a variety of industries globally, has shown interest in our company, our market and our country. We will continue to work at the level of excellence that has always characterized us. And now together with CDPQ, we will continue to grow and consolidate Grupo Diagnóstico Aries as a world-class company,” said Ernesto Lopez Clariond, Chairman of the Board of Directors of Empresas Aries.

“We are pleased to be investing in Grupo Diagnóstico Aries, who are committed to helping millions of people living in Mexico prevent, detect, and treat their health conditions,” said Martin Laguerre, Executive Vice-President and Head of Private Equity and Capital Solutions at CDPQ. “The management team have demonstrated sound strategic thinking and strong operating capabilities to drive the Company’s success to date. We look forward to working with them to capitalize on growth and digitalization opportunities to create value and consolidate the Company’s position in the medical diagnostic service industry in Mexico“.

Grupo Diagnóstico Aries offers a comprehensive range of services in laboratory testing in the disciplines of toxicology, molecular biology with a COVID-19 focus, cytology and pathology, immunology, urinalysis, specialized tests, and other tests. The Company also performs a wide range of clinical laboratory procedures in medical imaging, radiology, audiology, endoscopy, cardiology/echocardiology and densitometry.